Clinical Trial Update: TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 study of TGRX-1942 for advanced solid tumors and/or relapsed/refractory hematologic malignancies is currently recruiting in China.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies
• Non-small Cell Lung Cancer
• Solid Tumors

Drugs mentioned

• TGRX-1942

Snippet

Sponsor: Shenzhen TargetRx Co., Ltd. | Conditions: Non Small Cell Lung Cancer, Advanced Solid Tumor | Phase 1 | Status: RECRUITING